Setting a new standard for the treatment of chronic inflammation. Press Releases Catch up on the latest news from Evommune. December 4, 2024 Evommune Presents Positive Clinical Results of its MRGPRX2 Antagonist (EVO756) at the 7th GA²LEN Global Urticaria Forum October 31, 2024 Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases September 3, 2024 Evommune Initiates Phase 2 Trial of EVO756, an Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria July 16, 2024 Evommune Announces Positive Proof-of-Concept Clinical Trial Results for its MRGPRX2 Antagonist (EVO756) June 24, 2024 Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio March 20, 2024 Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 Antagonist EVO756 in Greater China and Key Asian Countries January 18, 2024 Evommune Announces Initation of a Phase 1 Trial of its MRGPRX2 Antagonist for the Treatment of Chronic Spontaneous Urticaria November 28, 2023 Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration September 27, 2023 Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan June 28, 2023 Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team 12 We have a range of chronic inflammatory disease programs currently in development. See Our Pipeline
